Crinetics Pharmaceuticals Inc
CRNXHealthcare|Biotechnology|USA
$83.58
-0.04 (-0.05%)
Tangible Book
$12.16
Financials
Financial Snapshot
Market Cap
$8.85B
Enterprise Value
$1.24B
Revenue (TTM)
$18.1M
Net Income (TTM)
$-496.4M
Cash & Equivalents
—
Net Cash/Share
$11.12
Free Cash Flow (TTM)
$-419.5M
Operating CF (TTM)
$-414.2M
Debt/Equity
0.04
Cash Runway & Burn Rate
Cash on Hand
$0.00
Quarterly Burn
$103.5M
Monthly Burn
$34.5M
Est. Runway
—
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $12.2M | $14.2M | $163.9M | $118.4M | $170.9M | $333.7M | $334.4M | $558.6M | $1.35B | $1.03B | $1.29B | |
| Operating Cash Flow | $-5.5M | $-9.5M | $-19.5M | $-46.4M | $-62.0M | $-88.6M | $-115.2M | $-168.6M | $-230.2M | $-377.9M | $-414.2M | |
| Free Cash Flow | $-5.7M | $-9.8M | $-20.5M | $-46.9M | $-62.2M | $-89.0M | $-116.9M | $-173.3M | $-234.0M | $-383.7M | $-419.5M | |
| Capital Expenditure | $-190.0K | $-304.0K | $-1.1M | $-492.0K | $-186.0K | $-436.0K | $-1.7M | $-4.7M | $-3.8M | $-5.8M | $-5.3M | |
| Financing Cash Flow | $-53.0K | $11.8M | $170.2M | $67.0K | $114.6M | $252.7M | $122.0M | $391.2M | $1.01B | $40.6M | $426.0M |
R&D Spending
R&D (TTM)
$355.9M
R&D Intensity
1969.7%
R&D Growth YoY
+7.2%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.1M | $4.7M | $4.0M | $1.0M | $7.7M | $18.1M | |
| R&D Expense | $5.1M | $9.2M | $24.5M | $41.5M | $57.0M | $84.3M | $130.2M | $168.5M | $240.2M | $332.1M | $355.9M | |
| R&D % of Revenue | — | — | — | — | — | 7815.9% | 2749.1% | 4199.5% | 23114.1% | 4314.7% | 1969.7% | |
| SG&A | $1.5M | $1.9M | $6.7M | $13.5M | $18.0M | $24.5M | $42.4M | $58.1M | $99.7M | $191.3M | $206.6M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.1M | $4.7M | $4.0M | $1.0M | $7.7M | $18.1M | |
| Cost of Goods Sold | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.1M | $200.0K | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.1M | $4.7M | $4.0M | $1.0M | $6.6M | $17.9M | |
| R&D | $5.1M | $9.2M | $24.5M | $41.5M | $57.0M | $84.3M | $130.2M | $168.5M | $240.2M | $332.1M | $355.9M | |
| SG&A | $1.5M | $1.9M | $6.7M | $13.5M | $18.0M | $24.5M | $42.4M | $58.1M | $99.7M | $191.3M | $206.6M | |
| Operating Income | $-6.0M | $-9.1M | $-28.7M | $-53.8M | $-75.0M | $-107.7M | $-167.9M | $-222.6M | $-338.9M | $-516.8M | $-545.7M | |
| Interest Expense | $-11.0K | $-8.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | $-6.0M | $-9.2M | $-27.1M | $-50.4M | $-73.8M | $-107.6M | $-163.9M | $-214.5M | $-298.4M | $-465.1M | $-496.2M | |
| Net Income | $-6.0M | $-9.2M | $-27.1M | $-50.4M | $-73.8M | $-107.6M | $-163.9M | $-214.5M | $-298.4M | $-465.3M | $-496.4M | |
| EPS (Diluted) | -0.43 | -0.66 | -2.23 | -2.09 | -2.42 | -2.80 | -3.15 | -3.69 | -3.69 | -4.95 | -5.13 | |
| EBITDA | $-5.9M | $-9.0M | $-28.2M | $-52.9M | $-74.0M | $-106.8M | $-166.9M | $-221.5M | $-336.1M | $-512.9M | $-541.6M | |
| Shares Out. (M) | 13.88 | 13.88 | 12.14 | 24.18 | 30.45 | 38.44 | 51.98 | 58.07 | 80.78 | 94.06 | 104.10 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $12.2M | $14.2M | $45.0M | $40.3M | $93.1M | $200.7M | $32.7M | $54.9M | $264.5M | $101.5M | $114.3M | |
| Marketable Securities | $0.00 | $0.00 | $118.9M | $78.1M | $77.8M | $133.0M | $301.8M | $503.7M | $1.09B | $926.4M | $1.18B | |
| Total Current Assets | $12.4M | $15.2M | $166.7M | $123.3M | $177.5M | $344.7M | $345.2M | $574.2M | $1.38B | $1.05B | $1.32B | |
| Total Assets | $12.6M | $15.6M | $171.4M | $130.4M | $183.4M | $351.0M | $352.2M | $635.4M | $1.43B | $1.13B | $1.40B | |
| Total Current Liabilities | $890.0K | $897.0K | $7.9M | $8.3M | $10.5M | $16.0M | $27.7M | $43.9M | $59.7M | $85.1M | $71.1M | |
| Long-Term Debt | $163.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $18.8M | $30.6M | $11.2M | $13.2M | $14.5M | $19.1M | $35.8M | $96.2M | $109.8M | $134.2M | $120.7M | |
| Stockholders' Equity | $-6.2M | $-15.0M | $160.2M | $117.1M | $168.9M | $331.9M | $316.3M | $539.1M | $1.32B | $992.1M | $1.28B | |
| Retained Earnings | $-7.1M | $-16.3M | $-43.4M | $-93.8M | $-167.6M | $-275.3M | $-439.2M | $-653.7M | $-952.1M | $-1.42B | $-1.55B |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $-5.5M | $-9.5M | $-19.5M | $-46.4M | $-62.0M | $-88.6M | $-115.2M | $-168.6M | $-230.2M | $-377.9M | $-414.2M | |
| Capital Expenditure | $-190.0K | $-304.0K | $-1.1M | $-492.0K | $-186.0K | $-436.0K | $-1.7M | $-4.7M | $-3.8M | $-5.8M | $-5.3M | |
| Free Cash Flow | $-5.7M | $-9.8M | $-20.5M | $-46.9M | $-62.2M | $-89.0M | $-116.9M | $-173.3M | $-234.0M | $-383.7M | $-419.5M | |
| Investing Cash Flow | $-190.0K | $-304.0K | $-119.5M | $41.7M | $217.0K | $-56.5M | $-174.0M | $-200.4M | $-574.8M | $173.9M | $7.5M | |
| Financing Cash Flow | $-53.0K | $11.8M | $170.2M | $67.0K | $114.6M | $252.7M | $122.0M | $391.2M | $1.01B | $40.6M | $426.0M | |
| Issuance of Stock | $0.00 | $0.00 | $106.5M | $0.00 | $114.3M | $249.5M | $117.2M | $369.6M | $985.0M | $0.00 | $380.5M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $-59.0K | $0.00 | $0.00 | $0.00 | $-541.0K | $-15.0M | $0.00 | $-578.0K | |
| Issuance of Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Payments of Debt | $-48.0K | $-212.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $270.0K | $271.0K | $2.3M | $6.3M | $10.4M | $17.4M | $28.3M | $40.9M | $69.4M | $91.0M | $100.2M | |
| Net Change in Cash | $-5.7M | $2.0M | $31.3M | $-4.6M | $52.8M | $107.6M | $-167.2M | $22.2M | $209.6M | $-163.5M | $19.4M |
Dilution Tracker
Shares outstanding grew 170.8% over 5 years — significant dilution
Shares Outstanding
104M
5-Year Share Growth
+170.8%
Stock Issuance (TTM)
$380.5M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 13.88 | 13.88 | 12.14 | 24.18 | 30.45 | 38.44 | 51.98 | 58.07 | 80.78 | 94.06 | 104.10 | |
| YoY Change % | — | 0.0% | -12.5% | 99.1% | 25.9% | 26.2% | 35.2% | 11.7% | 39.1% | 16.4% | 10.7% | |
| Stock Issuance | $0.00 | $0.00 | $106.5M | $0.00 | $114.3M | $249.5M | $117.2M | $369.6M | $985.0M | $0.00 | $380.5M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $-59.0K | $0.00 | $0.00 | $0.00 | $-541.0K | $-15.0M | $0.00 | $-578.0K | |
| Stock Based Comp. | $270.0K | $271.0K | $2.3M | $6.3M | $10.4M | $17.4M | $28.3M | $40.9M | $69.4M | $91.0M | $100.2M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 86.0% | 98.9% | |
| Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -9990.9% | -3544.1% | -5547.2% | -32613.5% | -6714.8% | -3020.3% | |
| Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -9985.3% | -3460.4% | -5345.9% | -28720.7% | -6046.2% | -2747.2% | |
| EBITDA Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -9905.4% | -3523.3% | -5519.8% | -32345.4% | -6664.2% | -2997.5% | |
| FCF Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -8258.3% | -2467.0% | -4318.1% | -22525.3% | -4985.5% | -2321.7% | |
| ROE % | 0.0% | 0.0% | -37.3% | -36.4% | -51.6% | -43.0% | -50.6% | -50.2% | -32.0% | -40.2% | -43.0% | |
| ROA % | -47.8% | -65.0% | -29.0% | -33.4% | -47.0% | -40.3% | -46.6% | -43.4% | -28.8% | -36.3% | -38.9% | |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - | - |
Valuation
P/E (TTM)At Loss
HistoricalAt Loss / At Loss / At Loss
Industry Med.27.41
P/S461.77
Historical151.96 / 511.08 / 4335.00
Industry Med.9.51
P/B6.87
Historical2.01 / 3.47 / 6.87
Industry Med.2.93
EV/EBITDA-14.04
Historical-14.04 / -5.23 / -3.01
Industry Med.13.14
EV/Revenue420.76
Historical99.73 / 456.43 / 3898.55
Industry Med.8.71
P/FCF—
Historical— / — / —
Industry Med.27.54
Intrinsic Value Models
Tangible Book
$12.16
Net Current Assets
$11.410
Net-Net Working Capital
$11.17
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PE Ratio | N/A | N/A | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | |
| PS Ratio | - | - | - | - | - | 1014.64 | 201.10 | 515.65 | 3933.08 | 567.68 | 461.77 | |
| PB Ratio | 0.00 | 0.00 | 4.50 | 5.20 | 2.76 | 4.07 | 3.12 | 4.50 | 3.59 | 4.48 | 6.87 | |
| EV/EBITDA | 0.00 | 0.00 | -19.75 | -9.35 | -4.04 | -9.57 | -3.92 | -8.66 | -10.26 | -6.77 | -14.04 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 947.68 | 138.19 | 478.16 | 3319.50 | 450.84 | 420.76 |
Analyst Estimates & Quality
Altman Z-Score
42.35
Safe
Piotroski F-Score
3
Weak
Beneish M-Score
17.05
Possible Manipulator
Forward Estimates
| Metric | Current Year | Next Year | 2 Years Out |
|---|---|---|---|
| Revenue | $68.51M | $177.45M | $417.99M |
| Net Income | $-508.87M | $-447.31M | $-266.96M |
| EPS | -4.83 | -4.34 | -2.53 |
| Book Value per Share | 9.50 | 9.84 | 9.86 |
| Operating Cash Flow per Share | -4.28 | -3.45 | -1.96 |
| Operating CF | $-445.54M | $-359.14M | $-204.03M |
Dividends
Revenue Segments
By Business
| Segment | 2025 |
|---|---|
| Discovery, development, and commercialization of therapeutics for rare endocrine diseases and | $7.7M |
By Geography
| Segment | 2025 |
|---|---|
| United States | $7.7M |